Related Experiment Videos
Comparative study on alpha 1-adrenoceptor antagonist binding in human prostate and aorta
1Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Japan.
Summary
This study investigated alpha 1-adrenoceptor antagonists in human prostate and aorta tissues. YM617 demonstrated selective binding to prostatic alpha 1-adrenoceptors, suggesting potential therapeutic applications.
Area of Science:
- Pharmacology
- Molecular Biology
- Urology
Background:
- Alpha 1-adrenoceptors are key targets for treating conditions like benign prostatic hyperplasia.
- Understanding the tissue-specific binding of antagonists is crucial for drug development.
Purpose of the Study:
- To characterize the binding of [3H]-prazosin in human prostate and aortic membranes.
- To compare the affinities of various alpha 1-adrenoceptor antagonists, including YM617, in these tissues.
- To assess the selectivity of YM617 for prostatic alpha 1-adrenoceptors.
Main Methods:
- Radioligand binding assays using [3H]-prazosin.
- Competition binding studies with prazosin, YM617, naftopidil, and urapidil.
- Pharmacological characterization using chloroethylclonidine treatment.
Main Results:
- Specific binding of [3H]-prazosin was saturable and high-affinity in both human prostate and aorta.
- YM617 and naftopidil exhibited higher affinity for prostatic alpha 1-adrenoceptors compared to aortic ones.
- YM617 showed relative selectivity for human prostatic alpha 1-adrenoceptors.
Conclusions:
- YM617 is a selective antagonist of human prostatic alpha 1-adrenoceptors.
- These findings support YM617's potential as a therapeutic agent for prostate-related conditions.